Literature DB >> 21151734

On Voxel based Iso-Tumor Control Probabilty and Iso-Complication Maps for Selective Boosting and Selective Avoidance Intensity Modulated Radiotherapy.

Yusung Kim1, Wolfgang A Tomé.   

Abstract

Voxel based iso-Tumor Control Probability (TCP) maps and iso-Complication maps are proposed as a plan-review tool especially for functional image-guided intensity-modulated radiotherapy (IMRT) strategies such as selective boosting (dose painting) and conformal avoidance IMRT. The maps employ voxel-based phenomenological biological dose-response models for target volumes and normal organs. Two IMRT strategies for prostate cancer, namely conventional uniform IMRT delivering an EUD = 84 Gy (equivalent uniform dose) to the entire PTV and selective boosting delivering an EUD = 82 Gy to the entire PTV, are investigated, to illustrate the advantages of this approach over iso-dose maps. Conventional uniform IMRT did yield a more uniform isodose map to the entire PTV while selective boosting did result in a nonuniform isodose map. However, when employing voxel based iso-TCP maps selective boosting exhibited a more uniform tumor control probability map compared to what could be achieved using conventional uniform IMRT, which showed TCP cold spots in high-risk tumor subvolumes despite delivering a higher EUD to the entire PTV. Voxel based iso-Complication maps are presented for rectum and bladder, and their utilization for selective avoidance IMRT strategies are discussed. We believe as the need for functional image guided treatment planning grows, voxel based iso-TCP and iso-Complication maps will become an important tool to assess the integrity of such treatment plans.

Entities:  

Year:  2008        PMID: 21151734      PMCID: PMC3000747          DOI: 10.1111/j.1617-0830.2008.00118.x

Source DB:  PubMed          Journal:  Imaging Decis (Berl)        ISSN: 1433-3317


  31 in total

Review 1.  Optimized radiation therapy based on radiobiological objectives.

Authors:  A Brahme
Journal:  Semin Radiat Oncol       Date:  1999-01       Impact factor: 5.934

Review 2.  Repopulation in radiation oncology: perspectives of clinical research.

Authors:  S M Bentzen
Journal:  Int J Radiat Biol       Date:  2003-07       Impact factor: 2.694

3.  Faster repair of DNA double-strand breaks in radioresistant human tumor cells.

Authors:  J L Schwartz; J Rotmensch; S Giovanazzi; M B Cohen; R R Weichselbaum
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-10       Impact factor: 7.038

4.  Comparing step-and-shoot IMRT with dynamic helical tomotherapy IMRT plans for head-and-neck cancer.

Authors:  Marco van Vulpen; Colin Field; Cornelis P J Raaijmakers; Matthew B Parliament; Chris H J Terhaard; Marc A MacKenzie; Rufus Scrimger; Jan J W Lagendijk; B Gino Fallone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-01       Impact factor: 7.038

5.  Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation.

Authors:  Richard A Popple; Roger Ove; Sui Shen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

6.  A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung.

Authors:  Sarah M McGuire; Sumin Zhou; Lawrence B Marks; Mark Dewhirst; Fang-Fang Yin; Shiva K Das
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-01       Impact factor: 7.038

7.  Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy.

Authors:  R R Weichselbaum; M A Beckett; J L Schwartz; A Dritschilo
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-09       Impact factor: 7.038

8.  A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density.

Authors:  S Webb; A E Nahum
Journal:  Phys Med Biol       Date:  1993-06       Impact factor: 3.609

9.  Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance.

Authors:  Brian P Yaremko; Thomas M Guerrero; Josue Noyola-Martinez; Rudy Guerra; David G Lege; Linda T Nguyen; Peter A Balter; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-29       Impact factor: 7.038

10.  Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).

Authors:  T Rancati; C Fiorino; G Gagliardi; G M Cattaneo; G Sanguineti; V Casanova Borca; C Cozzarini; G Fellin; F Foppiano; G Girelli; L Menegotti; A Piazzolla; V Vavassori; R Valdagni
Journal:  Radiother Oncol       Date:  2004-10       Impact factor: 6.280

View more
  4 in total

1.  Radiobiological model-based bio-anatomical quality assurance in intensity-modulated radiation therapy for prostate cancer.

Authors:  Ji-Yeon Park; Jeong-Woo Lee; Jin-Beom Chung; Kyoung-Sik Choi; Yon-Lae Kim; Byung-Moon Park; Youhyun Kim; Jungmin Kim; Jonghak Choi; Jae-Sung Kim; Semie Hong; Tae-Suk Suh
Journal:  J Radiat Res       Date:  2012-08-21       Impact factor: 2.724

2.  Risk-adaptive volumetric modulated arc therapy using biological objective functions for subvolume boosting in radiotherapy.

Authors:  Nicholas Hardcastle; Wolfgang A Tome
Journal:  Comput Math Methods Med       Date:  2012-06-27       Impact factor: 2.238

3.  Three-dimensional dose prediction and validation with the radiobiological gamma index based on a relative seriality model for head-and-neck IMRT.

Authors:  Noriaki Hamatani; Iori Sumida; Yutaka Takahashi; Michio Oda; Yuji Seo; Fumiaki Isohashi; Keisuke Tamari; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2017-09-01       Impact factor: 2.724

4.  Dosimetric and radiobiological characterizations of prostate intensity-modulated radiotherapy and volumetric-modulated arc therapy: A single-institution review of ninety cases.

Authors:  Muhammad Isa Khan; Runqing Jiang; Alexander Kiciak; Jalil Ur Rehman; Muhammad Afzal; James C L Chow
Journal:  J Med Phys       Date:  2016 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.